CA AB1103

Requires the Research Advisory Panel to review research projects conducted in California that involve administering Schedule I or Schedule II controlled substances, and authorizes the panel to approve such projects

Creates an expedited review process (until January 1, 2028) allowing the panel chairperson to assign 2 or more panel members to review and approve eligible research applications without a full panel vote, for projects that have federal approvals (DEA registration, FDA investigational new drug approval) and independent peer review

Authorizes the panel to withdraw approval from research projects for reasonable cause, but requires written notice and a reasonable cure period before withdrawal takes effect

Extends until January 1, 2028 the authorization for the Research Advisory Panel to hold closed sessions when reviewing applications containing trade secrets, intellectual property, or proprietary information

Requires the panel to report to the Legislature by January 1, 2026 on the backlog of applications, including how many have been reviewed and how many remain pending